Emgality® ▼ (galcanezumab): Use with anticoagulant treatments

Potential Drug-Drug Interactions With Anticoagulants or Other Drugs/Substances Involved With Clotting

Pharmacokinetic Characteristics

As a humanised IgG4 monoclonal antibody, galcanezumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.^1,2

As such, it is not expected to

• inhibit metabolic or induce enzymatic pathways

• be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, and

• produce any active metabolites.^2-4

Drug Interactions Studies Were Not Conducted

No drug interaction studies were conducted. No pharmacokinetic drug interactions are expected based on the characteristics of galcanezumab.¹

There are no known interactions for galcanezumab, drug-drug or otherwise.³

References

1. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

4. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. https://doi.org/10.1002/jps.20178

Glossary

CGRP = calcitonin gene-related peptide

IgG = immunoglobulin G

IgG4 = immunoglobulin G (subclass) 4

PK = pharmacokinetics

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.